The private equity firm is talking to potential advisers and the sale process could start as soon as later this year, the people said, asking not to be identified as the information is private.
Considerations are at an early stage and Permira could still opt to keep the business, the people said. A representative for Permira declined to comment.
Neuraxpharm develops and ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.